Safety alerts
27 safety alerts appeared in United Kingdom during Week 16, 2026. Safety concentration usually matters to quality, vigilance, and post-market surveillance teams because it can reveal emerging field risks.
United Kingdom medical device regulatory intelligence, Week 16, 2026.
Signals from 2026-04-13 to 2026-04-19, covering safety alerts, regulatory changes, device registrations, market movement, and source activity for United Kingdom.
Signals
34
Sources
5
Index status
Indexable
EXECUTIVE SUMMARY
United Kingdom generated 34 qualifying medical device signals during Week 16, 2026. Safety alerts led the week with 27 signals, while FDA Device Enforcement was the most active source. MHRA and eBay removed 215 listings of potentially dangerous medicines to enhance public health safety. MHRA approves single-dose 7.2mg semaglutide pen for adult obesity treatment.
Key observations
Safety alerts accounted for 27 of 34 qualifying signals, making it the main review lane for the week.
Competitor moves formed the second-largest cluster, which is useful context for teams separating safety work from regulatory and market monitoring.
FDA Device Enforcement contributed 27 signals, so source-level follow-up should start there.
Enforcement appeared repeatedly in the highlighted signals, which may warrant closer product, manufacturer, or competitor tracking.
Category interpretation
Competitor moves
2 competitor moves appeared in United Kingdom during Week 16, 2026. Competitor-linked activity is most useful when paired with product codes, indication context, and adjacent safety signals.
Competitor launches
2 competitor launches appeared in United Kingdom during Week 16, 2026. Competitor-linked activity is most useful when paired with product codes, indication context, and adjacent safety signals.
Regulatory changes
1 regulatory changes appeared in United Kingdom during Week 16, 2026. Regulatory-change activity should be checked against MHRA requirements, guidance, and downstream compliance workflows.
Recommended monitoring focus
- Review MHRA safety and recall activity for product categories that overlap your portfolio.
- Check whether new UK regulatory changes affect submission, labeling, vigilance, or post-market workflows.
- Review competitor-linked signals for launch timing, market access movement, and product category momentum.
- Use market trend signals to brief commercial, strategy, and market access teams alongside regulatory stakeholders.
Source-backed signal evidence
These source-linked items support the weekly analysis above. They are included for verification and follow-up, not as a raw feed export.
Medicines and Healthcare products Regulatory Agency·Competitor moves·
MHRA and eBay working in partnership to safeguard public health
MHRA and eBay removed 215 listings of potentially dangerous medicines to enhance public health safety.
SourceMedicines and Healthcare products Regulatory Agency·Competitor launches·
Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity
MHRA approves single-dose 7.2mg semaglutide pen for adult obesity treatment.
SourceMedicines and Healthcare products Regulatory Agency·Regulatory changes·
Transparency data: MHRA annual accountability review minutes
The MHRA annual accountability review minutes detail regulatory oversight and performance evaluations.
SourceSTAT News·Competitor launches·
STAT+: Pharmalittle: We’re reading about Lilly weight loss pill trial results, slashed U.K. clinical trial times, and more
Eli Lilly's Foundayo trial shows reduced cardiovascular risks in obese type 2 diabetes patients, easing safety concerns.
SourcePLOS Medicine·Market signals·
Rapid diagnostic tests, laboratory-based immunoassay and nucleic acid testing strategies for long-acting injectable pre-exposure prophylaxis: A systematic review
LAI-PrEP testing strategies show similar HIV detection rates but RDTs offer faster results and lower costs.
SourceEndpoints News·Competitor moves·
Trevi raises $150M; Spain and Boston set up biotech fund
Trevi Therapeutics plans to raise $150M by selling over 11.5 million shares at $13 each.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: ALLURA Xper FD20 OR Table; System Code: (1) 722015, (2)722023, (3)722035; (PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.)
Philips recalls ALLURA Xper FD20 OR Table due to intermittent X-ray imaging issues with the foot switch.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: Artoura Breast Tissue Expanders Reference Numbers: SDC-100H SDC-110H SDC-120H SDC-130H SDC-135H SDC-140H SDC-150H SDC-155H Smooth High Profile Tissue Expander, 225cc, 300cc, 375cc, 475cc, 500cc, 600 (Mentor Texas, LP.)
Mentor Texas, LP. recalls Class II Artoura Breast Tissue Expanders due to potential blunt needle tips.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: Paradigm Insulin Pump (MMT-712, MMT-715) (Medtronic MiniMed, Inc.)
Medtronic MiniMed's Paradigm Insulin Pumps are recalled due to risks of insulin over- and under-delivery affecting patient safety.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: CPX 4 US Breast Tissue Expanders with Suture Tabs Reference Numbers: 354-9113, 3549313, 354-9314 SILTEX Low Height Tissue Expander Style (9100, 450cc), (9300, 450cc), (9300, 550cc) (Mentor Texas, LP.)
Mentor Texas, LP. recalls Class II CPX 4 US Breast Tissue Expanders due to potential blunt needle tips.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: Azurion 5 M12; System Code: (1)722227, (2)722231; (PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.)
Philips recalled Azurion 5 M12 due to intermittent X-ray imaging issues with the wired foot switch.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: Atellica CH Enzymatic Hemoglobin A1c (A1c_E); Siemens Material Number (SMN): 11097536; (Siemens Healthcare Diagnostics, Inc.)
Siemens recalls Atellica CH A1c_E due to potential negative bias affecting diabetes diagnosis.
SourceSafety alerts
FDA Device Enforcement·Safety alerts·
Enforcement Class II: ALLURA Xper FD20 OR Table; System Code: (1) 722015, (2)722023, (3)722035; (PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.)
Philips recalls ALLURA Xper FD20 OR Table due to intermittent X-ray imaging issues with the foot switch.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: Artoura Breast Tissue Expanders Reference Numbers: SDC-100H SDC-110H SDC-120H SDC-130H SDC-135H SDC-140H SDC-150H SDC-155H Smooth High Profile Tissue Expander, 225cc, 300cc, 375cc, 475cc, 500cc, 600 (Mentor Texas, LP.)
Mentor Texas, LP. recalls Class II Artoura Breast Tissue Expanders due to potential blunt needle tips.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: Paradigm Insulin Pump (MMT-712, MMT-715) (Medtronic MiniMed, Inc.)
Medtronic MiniMed's Paradigm Insulin Pumps are recalled due to risks of insulin over- and under-delivery affecting patient safety.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: CPX 4 US Breast Tissue Expanders with Suture Tabs Reference Numbers: 354-9113, 3549313, 354-9314 SILTEX Low Height Tissue Expander Style (9100, 450cc), (9300, 450cc), (9300, 550cc) (Mentor Texas, LP.)
Mentor Texas, LP. recalls Class II CPX 4 US Breast Tissue Expanders due to potential blunt needle tips.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: Azurion 5 M12; System Code: (1)722227, (2)722231; (PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.)
Philips recalled Azurion 5 M12 due to intermittent X-ray imaging issues with the wired foot switch.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: Atellica CH Enzymatic Hemoglobin A1c (A1c_E); Siemens Material Number (SMN): 11097536; (Siemens Healthcare Diagnostics, Inc.)
Siemens recalls Atellica CH A1c_E due to potential negative bias affecting diabetes diagnosis.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: MiniMed 620G Insulin Pump (MMT-1750) (Medtronic MiniMed, Inc.)
Medtronic's MiniMed 620G insulin pump recalled due to risks of insulin over- and under-delivery affecting patient safety.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: CPX 4 US Breast Tissue Expanders with Suture Tabs Reference Numbers: SCPX-113TH, SCPX-123TH, SCPX-140TH, SCPX-146TH Smooth Tall Height Tissue Expander, 350cc, 450cc, 650cc, 750cc (Mentor Texas, LP.)
Mentor Texas recalls Class II CPX 4 US Breast Tissue Expanders due to potential blunt needle tips.
SourceCompetitor moves
Medicines and Healthcare products Regulatory Agency·Competitor moves·
MHRA and eBay working in partnership to safeguard public health
MHRA and eBay removed 215 listings of potentially dangerous medicines to enhance public health safety.
SourceEndpoints News·Competitor moves·
Trevi raises $150M; Spain and Boston set up biotech fund
Trevi Therapeutics plans to raise $150M by selling over 11.5 million shares at $13 each.
SourceCompetitor launches
Medicines and Healthcare products Regulatory Agency·Competitor launches·
Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity
MHRA approves single-dose 7.2mg semaglutide pen for adult obesity treatment.
SourceSTAT News·Competitor launches·
STAT+: Pharmalittle: We’re reading about Lilly weight loss pill trial results, slashed U.K. clinical trial times, and more
Eli Lilly's Foundayo trial shows reduced cardiovascular risks in obese type 2 diabetes patients, easing safety concerns.
SourceRegulatory changes
Medicines and Healthcare products Regulatory Agency·Regulatory changes·
Transparency data: MHRA annual accountability review minutes
The MHRA annual accountability review minutes detail regulatory oversight and performance evaluations.
SourceMarket signals
PLOS Medicine·Market signals·
Rapid diagnostic tests, laboratory-based immunoassay and nucleic acid testing strategies for long-acting injectable pre-exposure prophylaxis: A systematic review
LAI-PrEP testing strategies show similar HIV detection rates but RDTs offer faster results and lower costs.
SourceIndustry events
Medicines and Healthcare products Regulatory Agency·Industry events·
Promotional material: National AI Commission: Ask Me Anything
The MHRA is hosting a live session on AI regulation in healthcare.
SourceTrack these signals continuously.
MedFlux monitors regulators and medical device market sources across priority countries so regulatory, quality, and strategy teams can review changes without manually checking agency databases.